|
Patent landscape, scope, and claims: |
United States Patent 9,439,906 (Paliperidone Palmitate)
US Patent 9,439,906 claims dosing regimens for intramuscular paliperidone palmitate with structured “loading” and “monthly” maintenance schedules, with additional limitations for injection site, patient population (including renal impairment), and specific formulation attributes (aqueous nanoparticle suspension with particle-size and composition ranges).
What do the independent claims cover?
Claim 1 (core regimen; schizophrenia-spectrum; standard dosing ranges)
Claim 1 is a dosing regimen for a psychiatric patient “in need of treatment” for schizophrenia, schizoaffective disorder, or schizophreniform disorder, comprising:
- Day 1 (loading dose): intramuscular injection in the deltoid of a first loading dose of about 150 mg-eq. paliperidone as paliperidone palmitate in a sustained release formulation.
- Day 6 to Day 10 (second loading dose): intramuscular injection in the deltoid of a second loading dose of about 100 mg-eq. paliperidone as paliperidone palmitate in the sustained release formulation.
- ~1 month after second loading (first maintenance dose): intramuscular injection in the deltoid or gluteal muscle of a first maintenance dose of about 25 mg-eq. to 150 mg-eq. paliperidone as paliperidone palmitate in the sustained release formulation, administered a month (±7 days) after the second loading dose.
Claim 4 (core regimen; “psychotic disorder”; timing variant)
Claim 4 covers a dosing regimen for a “psychiotic patient in need of treatment for psychotic disorder,” comprising:
- Day 1: intramuscular in the deltoid of first loading dose about 150 mg-eq.
- Day 8 (timing variant): intramuscular in the deltoid of second loading dose about 100 mg-eq. on the eighth day.
- ~1 month after second loading: intramuscular in deltoid or gluteal of first maintenance dose about 25 mg-eq. to 150 mg-eq. a month (±7 days) after the second loading dose.
Claim 8 (renally impaired population; reduced dosing ranges)
Claim 8 is a regimen for renally impaired psychiatric patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder, comprising:
- Day 1: intramuscular in the deltoid of first loading dose 75 mg-eq. (about 75 mg-eq.)
- Day 6 to Day 10: intramuscular in deltoid of second loading dose 75 mg-eq. (about 75 mg-eq.) during 6th to 10th day
- ~1 month after second loading: intramuscular in deltoid or gluteal of first maintenance dose about 25 mg-eq. to 75 mg-eq. a month (±7 days) after the second loading dose
Claim 11 (renally impaired population; timing and maintenance band variant)
Claim 11 is similar to claim 8 but:
- Day 8 (timing variant): second loading dose on the eighth day
- Maintenance range: first maintenance dose about 25 mg-eq. to 50 mg-eq. (rather than up to 75 mg-eq.)
How do the dependent claims narrow coverage?
Injection-site and interval constraints (monthly dosing)
- Claim 2: After first maintenance dose in claim 1, subsequent maintenance doses are 25 mg-eq. to 150 mg-eq. administered in deltoid or gluteal at monthly (±7 days) intervals.
- Claim 9: After first maintenance dose in claim 8, subsequent maintenance doses are 25 mg-eq. to 150 mg-eq. at monthly (±7 days) intervals.
- Claim 15: After first maintenance dose in claim 4, subsequent maintenance doses are 25 mg-eq. to 150 mg-eq. at monthly (±7 days) intervals.
- Claim 16: After first maintenance dose in claim 11, subsequent maintenance doses are 25 mg-eq. to 150 mg-eq. at monthly (±7 days) intervals.
These dependent provisions matter because they convert the regimen from a one-time “first maintenance” schedule into a continued monthly maintenance dosing framework, with specific dose bands and injection sites.
Formulation specificity: aqueous nanoparticle suspension
- Claim 3 and Claim 5 and Claim 10 and Claim 12: the sustained release formulation is an aqueous nanoparticle suspension.
- Claim 17: specifies a composition and particle characteristics for the nanoparticle suspension used in claims 1, 4, 8, or 11, including:
- 3 to 20% (w/v) paliperidone palmitate; d50 900 nm to 1600 nm
- 0.5 to 3% (w/v) polysorbate 20 (wetting agent)
- buffering agents to render neutral to slightly basic (claimed as pH 8.5)
- 0.5 to 3% (w/v) polyethylene glycol 4000 (suspending agent)
- up to 2% (w/v) preservatives
- water q.s. ad 100%
- Claim 18: the suspension has 156 mg/mL paliperidone palmitate.
- Claim 19: an aqueous nanoparticle suspension that “consists essentially of” a more concrete formulation (tightened composition):
- 156 mg/mL paliperidone palmitate; d50 1600 nm to 900 nm
- 12 mg/mL polysorbate 20
- buffering agents to near slightly basic
- 30 mg/mL polyethylene glycol 4000
- water q.s. ad 100%
- Claim 20: buffering agents are specifically citric acid monohydrate, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, and sodium hydroxide.
- Claim 21: pH is 7 to 7.5 (this claim narrows the earlier “neutral to very slightly basic (pH 8.5)” description into an explicit lower band).
Disease-type narrowing
- Claim 6/Claim 7/Claim 13/Claim 14/Claim 6-7: schizophrenia and schizoaffective disorder are explicitly called out in narrower dependent claims for the psychotic disorder and renally impaired variants.
- Claim 4 includes a general “psychotic disorder” framing; dependent claims specify schizophrenia and schizoaffective disorder.
What is the claim “shape” from a freedom-to-operate perspective?
The patent landscape impact comes from two separate layers:
-
Method-of-treatment regimen structure
- Loading dose on Day 1
- Second loading dose on Day 6 to 10 or specifically Day 8
- First maintenance about 1 month ±7 days after the second loading dose
- Maintenance continues monthly at ±7 days
- Injection sites constrained to deltoid for loading and either deltoid or gluteal for maintenance
-
Formulation identity
- “Sustained release formulation” is not left open once composition-dependent claims are invoked.
- Nanoparticle suspension is defined by:
- paliperidone palmitate concentration bands
- d50 particle size window
- excipient identity and concentration ranges
- pH constraints and, in narrower dependent claims, explicit buffering agent set
As a result, a competitor’s generic or follow-on will need to navigate both:
- whether their dosing schedule matches the claimed timing and injection-site requirements, and
- whether their formulation falls within the nanoparticle suspension definition and the specific composition/pH constraints.
Key regimen parameters claimed (consolidated table)
| Claim set |
Population / disorder framing |
Loading #1 |
Loading #2 timing window |
Loading #2 site |
Maintenance start |
Maintenance dose range |
Maintenance site / interval |
| Claim 1 |
schizophrenia/schizoaffective/schizophreniform |
Day 1, deltoid, ~150 mg-eq. |
Day 6 to 10, deltoid, ~100 mg-eq. |
deltoid |
1 month (±7 days) after loading #2 |
~25 to 150 mg-eq. |
deltoid or gluteal; monthly (±7 days) covered via claim 2 |
| Claim 4 |
psychotic disorder (with dependent disease narrowing) |
Day 1, deltoid, ~150 mg-eq. |
Day 8, deltoid, ~100 mg-eq. |
deltoid |
1 month (±7 days) after loading #2 |
~25 to 150 mg-eq. |
deltoid or gluteal; subsequent monthly (±7) via claim 15 |
| Claim 8 |
renal impairment; schizophrenia-spectrum |
Day 1, deltoid, ~75 mg-eq. |
Day 6 to 10, deltoid, ~75 mg-eq. |
deltoid |
1 month (±7 days) after loading #2 |
~25 to 75 mg-eq. |
deltoid or gluteal; subsequent monthly via claim 9 (note range differs: subsequent up to 150 mg-eq.) |
| Claim 11 |
renal impairment; psychotic disorder (dependent disease narrowing) |
Day 1, deltoid, ~75 mg-eq. |
Day 8, deltoid, ~75 mg-eq. |
deltoid |
1 month (±7 days) after loading #2 |
~25 to 50 mg-eq. |
deltoid or gluteal; subsequent monthly via claim 16 (again range differs: subsequent up to 150 mg-eq.) |
Formulation scope: nanoparticle suspension claims (consolidated constraints)
Broad formulation range (Claim 17)
- paliperidone palmitate: 3 to 20% (w/v)
- particle size: d50 1600 nm to 900 nm
- wetting agent: polysorbate 20 0.5 to 3% (w/v)
- buffering to neutral to slightly basic: described as pH 8.5
- suspending agent: PEG 4000 0.5 to 3% (w/v)
- preservatives: up to 2% (w/v)
- water q.s. ad 100%
Tight composition “anchor” (Claims 18-21)
- paliperidone palmitate concentration: 156 mg/mL
- polysorbate 20: 12 mg/mL
- PEG 4000: 30 mg/mL
- buffering agents: explicitly named set (Claim 20)
- pH: 7 to 7.5 (Claim 21)
This means the claim set is designed so that a composition that matches the specific “consists essentially of” formulation will land inside the narrowest formulation-dependent claim layer.
Practical claim-coverage maps (where design-arounds succeed or fail)
1) Timing and injection-site are the first gate
The regimen requires:
- Day 1 deltoid first loading
- deltoid second loading (either Day 6 to 10 or Day 8 depending on the claim)
- deltoid or gluteal for maintenance, beginning around 1 month ±7 days
- monthly maintenance thereafter with ±7-day flexibility
Design-arounds that keep injections in deltoid for loading but shift second-loading timing outside Day 6 to 10 and outside exact Day 8 could avoid the claim window, but only if maintenance timing and all other constraints also remain outside the claimed limits.
2) Dose bands create another gate
There are two independent “dose band” frameworks:
- standard: first loading about 150 mg-eq., second about 100 mg-eq., maintenance 25 to 150 mg-eq.
- renally impaired: first loading about 75 mg-eq., second about 75 mg-eq., maintenance initially restricted to 25 to 75 mg-eq. (claim 8) or 25 to 50 mg-eq. (claim 11), with subsequent maintenance ranges changing in dependent claims.
Notably, dependent claims 9, 16 expand subsequent maintenance ranges back out to 25 to 150 mg-eq. even in the renally impaired pathway. That raises the importance of whether the regimen is read as a continuation schedule versus only the first maintenance.
3) Formulation match is a second gate
If a competitor’s formulation is not an “aqueous nanoparticle suspension,” or if it does not meet particle-size/d50 ranges and excipient/pH constraints, it may avoid the narrower formulation-dependent claims (3, 5, 10, 12, 17-21). If the product is used only in a regimen claim that does not require the nanoparticle limitation, then formulation scope may be less decisive.
What does this imply about the patent landscape for competitors?
Within the boundaries of the claims provided, the patent is structured to capture:
- a paliperidone palmitate dosing “pattern” with clinically plausible day ranges and a “±7 days” operational window for monthly injections, and
- a specific formulation architecture (aqueous nanoparticle suspension with defined excipients and particle-size behavior).
That structure typically places pressure on both:
- regimen selection in clinical practice and label-driven schedules, and
- formulation development to avoid crossing the “aqueous nanoparticle suspension” and “consists essentially of” constraints.
Key Takeaways
- US 9,439,906 claims paliperidone palmitate dosing regimens with Day 1 deltoid loading, deltoid second loading (either Day 6 to 10 or Day 8), and monthly maintenance starting about 1 month (±7 days) after loading #2.
- The claim set includes renal impairment variants that start with ~75 mg-eq. loading doses and impose narrower initial maintenance dose bands, then broadens subsequent maintenance dosing ranges in dependent claims.
- Several claims hinge on the formulation being an aqueous nanoparticle suspension with defined d50 particle-size windows and excipient/pH constraints, including a 156 mg/mL paliperidone palmitate target and a pH 7 to 7.5 limitation in narrower dependent claims.
FAQs
-
Does the patent require deltoid injections for both loading doses?
Yes. Claim 1 and claim 4 require deltoid for both loading doses; claim 8 and claim 11 likewise require deltoid for both loading doses.
-
What is the key difference between the Day 6 to 10 and Day 8 versions?
Claim 1 uses Day 6 to 10 for the second loading dose, while claim 4 uses the eighth day specifically. The same pattern appears in the renal impairment claims (claim 8 uses Day 6 to 10, claim 11 uses Day 8).
-
How much flexibility is allowed for monthly maintenance timing?
The maintenance start and subsequent monthly doses use “a month (±7 days)” and monthly (±7 days) language, which creates a defined window rather than an exact calendar month.
-
Is the nanoparticle formulation required in every claim?
No. The nanoparticle suspension appears as a limitation in specific dependent claims (e.g., claim 3, 5, 10, 12, and the formulation-specific claims 17-21).
-
Do renally impaired claims restrict only the first maintenance dose or the full maintenance schedule?
The independent renally impaired claims define the first maintenance dose range (claim 8: 25 to 75 mg-eq.; claim 11: 25 to 50 mg-eq.). Dependent claims 9 and 16 then define subsequent maintenance ranges at monthly (±7 days) intervals up to 150 mg-eq..
References
[1] United States Patent 9,439,906.
More… ↓
⤷ Start Trial
|
